Introduction
Research over the past several decades has identified the dynamic nature of collagen turnover in normal and diseased tissues, and an ever-expanding array of matrix functions that include the initiation and modulation of tissue growth and repair [1] . In the kidneys, lungs, and liver, fibrosis is considered a final common pathway to organ failure. This holds true for the heart as well [2] . Given the importance of fibrous tissue in leading to myocardial failure, non-invasive methods are needed to address fibrous tissue formation and degradation in cardiac diseases. The assessment of collagen-derived peptides released into the blood stream during fibrillar collagen metabolism has been proposed as a useful tool to address myocardial fibrosis from a distance [3] . This article will summarize in brief the rationale and the available experimental and clinical data obtained by applying this approach to address fibrosis in hypertensive heart disease, here defined as a greater than normal left ventricular mass (i.e. left ventricular hypertrophy) in the absence of a cause other than arterial hypertension.
Myocardial fibrosis in arterial hypertension
Myocardial fibrosis is present in the hypertensive heart A number of studies performed in postmortem human hearts [4] [5] [6] and endomyocardial human biopsies [7] [8] [9] have shown that the myocardial collagen volume fraction, a morphometric measure of the amount of tissue collagen, is constantly increased in hypertensive patients, either without or with left ventricular hypertrophy, compared with normotensive controls. Furthermore, immunohistochemical analysis shows exaggerated accumulation of fibrillar collagen types I and III within the myocardial interstitium and surrounding intra-mural coronary arteries and arterioles ( Fig. 1) [10] . Myocardial fibrosis is the result of both increased collagen types I and III synthesis by fibroblasts and unchanged or decreased extracellular collagen degradation by matrix metalloproteinases [11] . Hemodynamic and non-hemodynamic factors are involved in this disequilibrium in collagen metabolism that occurs in hypertension [11] .
Myocardial fibrosis has a detrimental clinical impact
Although several other risk factors of heart failure have been identified, arterial hypertension is the most common risk factor in the general population [12, 13] . A number of clinical studies suggest that histologically proven myocardial fibrosis predisposes to ventricular diastolic and systolic dysfunction and other cardiac alterations, which in turn confer increased risk of heart failure to patients with hypertensive heart disease [14] . This is supported by the fact that in athletes with left ventricular hypertrophy, myocardial fibrosis does not develop and there is no associated risk of heart failure [15] . Myocardial collagen volume fraction has been shown to be a major determinant of increased diastolic stiffness [16] and decreased systolic ejection fraction [17] in patients with hypertensive heart disease. In addition, it has been reported that left ventricular arrhythmias in these patients are related to the degree of myocardial fibrosis [18] . Finally, Schwartzkopff et al. [19] have demonstrated that total and perivascular collagen volume fraction correlated with the increased coronary resistance in hypertensives with reduced coronary flow reserve.
Myocardial fibrosis must be detected in hypertensive patients From the aforementioned considerations it emerges that determining the extent of collagen accumulation in myocardial tissue may be relevant in improving both the diagnosis and treatment of hypertensive heart disease. Although microscopic examination of cardiac biopsies is the most reliable method for documenting and measuring myocardial fibrosis, this is an invasive methodology not useful for wide-scale application, which may be subject to sampling error. Thus, the development of non-invasive methods (e.g. ultrasonic and biochemical) to indicate the presence of myocardial fibrosis in hypertensive patients would have a broader application.
Ultrasonic tissue characterization allows identification and characterization of the physical or physiological state of myocardium based on the analysis of the interactions between ultrasound and the tissue itself [20] . It is based on the principle that the interaction of ultrasound waves with normal tissue results in reflected ultrasonic signals that exhibit different characteristics, which are amenable to quantitation (one of the approaches being the measurement of tissue-integrated backscatter), that define the myocardial structure and functional attributes, and that these features are different from those obtained when ultrasound interacts with abnormal tissue (e.g. fibrotic tissue) [21] . In this regard, a correlation between alterations in echoreflectivity, namely diminution in the cyclic variation of backscatter signal, and histologically assessed collagen volume fraction was recently shown in the heart of hypertensive patients [7, 22] . However, it has been suggested that cyclic variation of backscatter signal reflects more directly the contractile properties of the myocardium [23] rather than measures of collagen content. Thus, alternative image analysis procedures are currently under evaluation. For instance, magnetic resonance imaging is another promising technique for characterizing the composition of the myocardium; especially, tissue characterization with the contrast agent gadolinium is well validated and provides insights quantifying non-ischemic fibrosis [24] .
Biochemical monitoring of fibrillar collagen metabolism
Collagen synthesis-derived peptides Fibrillar collagen types I and III are synthesized in the fibroblasts as procollagen precursors containing an aminoterminal and a carboxy-terminal propeptide [25] . After the precursor has been secreted into the extracellular space, the propeptides are removed by specific proteinases, allowing integration of the rigid collagen triple helix into the growing fibril ( Fig. 2) [25] . The released propeptides are found in an immunochemically intact form in blood.
If the amounts of propeptides released during cleavage that reach the circulation are proportional to the amount of fibrillar collagen formed, these would qualify as indices of collagen synthesis. This holds true for the carboxyterminal propeptide of procollagen type I (PICP) during its conversion to collagen type I [25] . In fact, a stoichiometric ratio of 1 : 1 exists between the number of collagen type I molecules produced and that of PICP molecules released. In contrast, the amino-terminal propeptide of procollagen type I (PINP) and the carboxy-terminal and amino-terminal propeptides of collagen type III (PIIICP and PIIINP, respectively) are not completely cleaved during the conversion of procollagen types I and III into collagen types I and III, respectively, so they remain in the final fibers, where they can be released during fiber degradation [26] .
Collagen degradation-derived peptides
The rate-limiting step in the degradation of collagen fibrils is catalytic cleavage by interstitial collagenase [27] . This enzyme cleaves all three a-chains of collagen at a single specific locus located at a distance threequarters of the way from the amino-terminal extreme (Fig. 2) . Whereas the large telopeptide remains within the interstitial space for further degradation by gelatinases, the small telopeptide is found in an immunochemically intact form in blood [27] .
Similarly to PICP, the amount of the cross-linked carboxy-terminal telopeptide resulting from the cleavage of collagen type I (CITP) by collagenase that reaches the circulation is proportional to the amount of fibrillar collagen degraded [25] . Therefore, CITP would qualify as an index of collagen degradation. In fact, a stoichiometric ratio of 1 : 1 exists between the number of collagen type I molecules degraded and that of CITP molecules released.
Factors influencing serum concentrations of collagen type I-derived peptides Although serum PICP and CITP reflect synthesis and degradation of collagen type I, respectively, it has to be taken into account that their serum concentrations depend also on other factors, including their rate of release, how they reach the blood (e.g. cardiac lymph versus venous drainage), and their volume of distribution [26] . Elimination of a peptide, its potential uptake, and its metabolism are other factors that need to be considered. Whereas PICP is metabolized by the liver, CITP is excreted by the kidney. Thus, hepatic or renal insufficiency could alter their clearance and raise their serum concentrations. In addition, serum concentrations of these peptides can be influenced by some inflammatory processes (i.e. associated with wound healing) and by chronic degenerative diseases (namely, metabolic bone diseases).
With these aspects in mind, a diversity of experimental and clinical observations have demonstrated that high serum concentrations of PICP in the setting of low or unchanged serum concentrations of CITP, measured by either radioimmunoassay or enzyme-linked immunosorbent assay using commercially available antisera, reflect histomorphologically proven ongoing fibrosis in organs such as the liver and the lung [28] .
Collagen type I-derived serum peptides in hypertensive heart disease The balance between PICP and CITP is altered in hypertensive heart disease We and other workers have measured the serum concentrations of PICP and CITP in spontaneously hypertensive rats (SHR) and in essential hypertensive patients with left ventricular hypertrophy and no associated conditions that alter collagen metabolism.
Collagen in hypertensive heart disease Ló pez et al. 1447 Serum PICP was found to be increased in hypertensives compared with normotensive subjects [29] [30] [31] [32] and in SHR compared with normotensive Wistar-Kyoto rats [33] [34] [35] [36] [37] . In addition, serum CITP concentrations were no different in hypertensives than in normotensives [30, 31, 38] or in SHR compared with Wistar-Kyoto rats [33] [34] [35] . As a consequence, the PICP-to-CITP ratio, an index of coupling between the synthesis and degradation of collagen type I [39] , was abnormally increased in both hypertensive patients [30, 31] and in SHR [33] [34] [35] (Fig. 3) . Therefore, if an equilibrium is to exist between collagen type I synthesis and degradation, as proposed by Laurent [40] , these findings suggest that the intensity of the extracellular degradation of collagen type I is not enough to equilibrate the increased extracellular synthesis of this molecule. This, in turn, can result in an excess of collagen type I deposition and organ fibrosis.
Serum PICP is a marker of myocardial fibrosis in hypertensive heart disease In previous studies we found that serum PICP directly correlated with the collagen volume fraction in the left ventricle of untreated [33] and treated SHR [34, 35] . Thus, serum PICP emerged as a potential marker of both hypertensive myocardial fibrosis and the antifibrotic effect of antihypertensive treatment in this model. We tested the clinical validity of this hypothesis in three studies performed in humans in whom transvenous endomyocardial biopsies were performed, and the collagen volume fraction was determined on picrosirius redstained tissue sections with an automated image analysis system. On one hand, we found that serum PICP concentrations correlated directly with the collagen volume fraction in hypertensive patients [16, 41] . In addition, using receiver operating characteristic curves, we observed that a cut-off point of 127 mg/l for PICP provided 78% specificity and 75% sensitivity for predicting severe myocardial fibrosis, with a relative risk of 4.80 (95% confidence interval, 1.19-10.30) [41] . Thus, serum PICP may be useful for screening for myocardial fibrosis in hypertensive patients.
On the other hand, we observed a strong association between treatment-induced changes in collagen volume fraction and treatment-induced changes in serum PICP in hypertensive patients [16, 42] . Furthermore, the ability of antihypertensive treatment to reduce blood pressure did not predict its capacity to either repair myocardial fibrosis or to normalize collagen type I synthesis in these patients. In fact, chronic angiotensin II type I receptor blockade with losartan, but not chronic calcium channel blockade with amlodipine, resulted in a decrease of both collagen volume fraction and PICP in hypertensive patients, despite an almost identical antihypertensive efficacy of the two compounds [42] . This observation provides clinical support to previous in vitro and in vivo experimental findings suggesting a direct role for angiotensin II-mediated collagen type I accumulation in the hypertensive heart [43] . In addition, there is experimental support for a contribution of aldosterone [44] , endothelin-1 [45] and transforming growth factor-b [46] to the fibrotic effects of angiotensin II in hypertensive heart disease.
Ló pez et al. [47] recently found that torasemide, but not furosemide, significantly reduced both serum PICP concentrations and cardiac fibrosis in biopsy specimens from hypertensives with symptomatic heart failure. Interestingly, torasemide, but not furosemide, has been reported to prevent cardiac uptake of aldosterone in heart failure patients [48] and to block the binding of the hormone to the mineralocorticoid receptor [49] . Other studies performed in patients with congestive heart failure have demonstrated the ability of the aldosterone antagonist spironolactone to reduce serum PICP in these patients [50] . Thus, the notion is emerging that aldosterone may promote cardiac fibrosis, probably through a direct action on cardiac cells. An amount of experimental evidence supports this possibility. In fact, aldosterone has been shown to stimulate collagen synthesis through the mineralocorticoid receptor in isolated cardiac fibroblasts [51] . In addition, in experiments on senescent normotensive rats and rats with renovascular hypertension, hyperaldosteronism, or spontaneous hypertension, the aldosterone antagonist spironolactone was able to prevent or reverse the development of myocardial fibrosis even though the drug did not change or normalize the blood pressure [52] [53] [54] [55] [56] .
The heart is a source of circulating PICP in hypertensive heart disease It is clear that PICP detectable in serum is not exclusively heart-specific. Thus, we recently determined PICP in blood from the antecubital vein and from the coronary sinus in hypertensive patients with and without heart failure [17] . We found that the concentration of PICP was significantly higher in coronary blood than in peripheral blood in hypertensive patients, but not in normotensive subjects (Fig. 4) . In addition, PICP measured in peripheral blood was directly correlated with PICP measured in coronary blood. Interestingly, associations were found between the increase in the extent of collagen type I deposition (as assessed immunohistochemically with specific antibodies) and the increase in coronary and peripheral PICP in hypertensive patients (Fig. 4) . Albeit preliminary, these findings suggest that circulating PICP detected in hypertensive patients is essentially of cardiac origin and that serum PICP is a reliable index of the amount of collagen type I present within the hypertensive myocardium.
Conclusions and perspectives
In hypertensive heart disease, it is not only the quantity of myocardium, but rather its quality that accounts for increased risk of heart failure. Thus, strategies directed Collagen in hypertensive heart disease Ló pez et al. 1449 Endomyocardial tissue from a normotensive control (upper panel), a patient with hypertensive heart disease and no clinical manifestations of heart failure (middle panel), and a patient with hypertensive heart disease and clinically overt heart failure (lower panel) stained with an antibody against collagen type I (Â 40). The myocardial surface area (MSA) with positive staining for collagen type I fibers (in brown) measured in each subject is presented on the right side. Serum concentrations of procollagen type I carboxy-terminal propeptide (PICP) measured in coronary and peripheral blood in each subject are presented in the central part. Adapted from [17] .
towards the identification of the changes in myocardial structure (e.g. fibrosis) involved in the transition from left ventricular hypertrophy to heart failure are likely to offer the greatest promise for reducing the incidence of heart failure and its associated mortality among hypertensive patients. The findings reviewed here suggest that serum PICP may be clinically useful for monitoring myocardial fibrosis in hypertensive heart disease. In fact, the measurement of serum PICP is easy to perform and analyze, and it has good performance characteristics and low cost. In addition, serum PICP makes physiological sense; that is, its changes reflect well the variations in collagen type I deposition in the myocardium. However, the available information has been observed in small populations and needs to be validated in larger long-term studies in which cardiac biopsy can be replaced by the non-invasive characterization of myocardial texture by analysis of ultrasonic reflectivity. In support of this approach are recent findings showing an association between diminished cyclic variation of backscatter signal and increased serum PICP in hypertensive patients with left ventricular hypertrophy [57, 58] .
Today's management of hypertensive heart disease should not simply focus on reduction in blood pressure and left ventricular mass; it must also target the adverse structural remodeling that begets this condition. As stated recently by the European Society of Hypertension and the European Society of Cardiology in the guidelines for the management of arterial hypertension, ''. . . future studies should investigate treatment-induced effects on indices of collagen content or fibrosis of the left ventricular wall, rather than on its mass only . . .'' [59] . In this conceptual framework, the time has come to design clinical trials aimed to determine whether variations in PICP induced by antihypertensive treatment are linked to changes in the outcome of patients with hypertensive heart disease, as suggested by a preliminary study in patients with heart failure of diverse etiology [50] .
